ALX Oncology Holdings Inc expected to post a loss of 72 cents a share - Earnings Preview

Reuters
2024-11-08

* ALX Oncology Holdings Inc is expected to show no change in quarterly revenue when it reports results for the period ending December 31 2024

*

* ​LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 72 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 0.4% in the last three months. ​

* Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $6.00​, above​ its last closing price of $1.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Sep. 30 2024 -0.78 -0.78 -0.58 Beat 25.6

Jun. 30 2024 -0.77 -0.77 -0.76 Beat 1.7

Jan. 1 0001 -0.85 -0.84 -0.71 Beat 15.1​

Dec. 31 2023 -0.81 -0.84 -0.93 Missed -10.5

​​Sep. -0.82 -0.87 -1.24 Missed -42.5

30 2023

Jun. 30 2023 -0.88 -0.88 -0.84 Beat 4.5​

Mar. 31 2023 -0.82 -0.80 -0.74 Beat 7.7

Dec. 31 2022 -0.81 -0.89 -0.75 Beat 15.4

This summary was machine generated November 8 at 15:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10